In focal epilepsy, seizures are generated by a localized, synchronous neuronal electrical discharge that may spread to large portions of the brain. In spite of intense research in the field of ...

Please provide your email address to receive an email when new articles are posted on . Cannabidiol treatment was associated with median reduction of 67% to 99% in focal aware seizures. All ...

About 60-70% of focal epilepsy patients achieve seizure control with first-line antiseizure medications (ASMs). Lamotrigine and levetiracetam demonstrate high efficacy and tolerability for seizure ...

Researchers studied more than 200 children with epilepsy and found that even if the cause of focal-onset seizures cannot be identified and they do not fit into a known epilepsy syndrome, long-term ...

Patients with focal nonmotor seizures experience a "disproportionate delay to diagnosis" compared with those with focal motor seizures, especially among teens, new research suggests. Retrospective ...

Two stress-reducing behavioral interventions may be effective in reducing seizures in adult patients with medication-resistant focal epilepsy, new research suggests. In a randomized trial of 64 ...

About one-third of patients with focal epilepsy, a common form of the neurological disorder, are believed to respond poorly to available therapies. Yet they, too, may eventually see improvement, if ...

People with epilepsy who experience focal seizures sometimes remain mobile but are unable to hear or respond to their environment. Yale School of Medicine researchers have discovered a surprising ...

University of California San Diego is conducting new, Phase 2/3 national epilepsy clinical research trials, called Rise, to study BHV-7000, a novel investigational therapy, in focal epilepsy.

Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Valproate (Depakene) emerged as the best first-line choice for ...

The first seizure clinic model enabled rapid diagnosis and treatment for children with epilepsy, according to data presented ...

(RTTNews) - Shares of Xenon Pharmaceuticals Inc. (XENE) closed Monday's trading at an all-time high of $31.50, gaining more than 100%, thanks to promising mid-stage data for focal epilepsy drug ...